| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/01/2006 | EP1509202A4 Novel high viscosity embolizing compositions comprising prepolymers |
| 02/01/2006 | EP1500654B1 Benzoxazinone derivatives, the preparation and use thereof as medicaments |
| 02/01/2006 | EP1487421B1 Pharmaceutical formulation for the active ingredient budesonide |
| 02/01/2006 | EP1476419B1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives |
| 02/01/2006 | EP1463707A4 A group of novel anti-cancer compounds with specific structure |
| 02/01/2006 | EP1436293B1 Polycyclic compounds having anti-tumor activity |
| 02/01/2006 | EP1425281B1 Tricyclic CRF receptor antagonists |
| 02/01/2006 | EP1383734B1 Compounds useful as intermediates for 4-aminoquinoline derivatives |
| 02/01/2006 | EP1370548B1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same |
| 02/01/2006 | EP1343492B1 Treatment of mucositis |
| 02/01/2006 | EP1341774B1 Fused heteroaromatic glucokinase activators |
| 02/01/2006 | EP1334082A4 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
| 02/01/2006 | EP1328266B1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 02/01/2006 | EP1268502B1 O-aryl glucoside sglt2 inhibitors and method |
| 02/01/2006 | EP1267827B1 Use of an aqueous solution for the treatment of try eye |
| 02/01/2006 | EP1254121B1 Preparation of sulfonamides |
| 02/01/2006 | EP1235812B1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 02/01/2006 | EP1225874B1 Antiviral solid dispersions |
| 02/01/2006 | EP1223953B1 Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| 02/01/2006 | EP1212376B1 Synthetic vegetal melanins, process for their production and compositions containing them |
| 02/01/2006 | EP1200479B1 Multiple cytokine-antibody complexes |
| 02/01/2006 | EP1194409B1 Pyrazolidinol compounds |
| 02/01/2006 | EP1169336B1 Ent-steroids as selectively active estrogens |
| 02/01/2006 | EP1158968B1 Jak-3 inhibitors for treating allergic disorders |
| 02/01/2006 | EP1150675B1 A transdermal composition of an antivomiting agent and a preparation containing the same |
| 02/01/2006 | EP1131302B1 Substituted 4-amino-2-aryl-cyclopenta [d]pyrimidines, their production and use and pharmaceutical preparations containing the same |
| 02/01/2006 | EP1119563B1 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 02/01/2006 | EP1115849B1 Genes of the 1-desoxy-d-xylulose biosynthetic pathway |
| 02/01/2006 | EP1104289B1 New oral formulation for 5-ht4 agonists or antagonists |
| 02/01/2006 | EP1080078B1 Heterocyclic compounds and methods to treat cardiac failure and other disorders |
| 02/01/2006 | EP1064402B1 Antisense modulation of lfa-3 |
| 02/01/2006 | EP1026243B1 NUCLEIC ACID CAPABLE OF BINDING SPECIFICALLY TO Ras TARGET PROTEIN |
| 02/01/2006 | EP1001804B1 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections |
| 02/01/2006 | EP0996738B1 Recombinant vector containing infectious, viral genome sequences greater than 100 kb, method for producing same and use for the mutagenesis of the viral sequences |
| 02/01/2006 | EP0994709A4 Calcium blockers to treat proliferative vitreoretinopathy |
| 02/01/2006 | EP0956040B1 Stimulation of host defense mechanisms against viral challenges |
| 02/01/2006 | EP0907736B1 Cc-type chemokines |
| 02/01/2006 | EP0898478B1 Stimulation of host defence mechanisms against tumors |
| 02/01/2006 | EP0885060B1 Solid or semi-solid hydrocarbon gels |
| 02/01/2006 | EP0859613B1 Use of flupirtin for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system |
| 02/01/2006 | EP0759297B1 Remedy for pulmonary heart |
| 02/01/2006 | CN1729291A Exon 1beta of PDGF receptor alpha gene and utilization thereof |
| 02/01/2006 | CN1729200A Macrolides |
| 02/01/2006 | CN1729197A Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| 02/01/2006 | CN1729196A Process for producing optically active sulfoxide |
| 02/01/2006 | CN1729192A Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
| 02/01/2006 | CN1729191A Pyrazoloquinolines with immunomodulating activity |
| 02/01/2006 | CN1729190A Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics |
| 02/01/2006 | CN1729189A Pyridino [2, 3-D] pyrimidine derivatives as selective KDR and FGFR inhibitors |
| 02/01/2006 | CN1729187A Substituted benzodioxepins |
| 02/01/2006 | CN1729186A Piperidine derivatives useful as CCR5 antagonists |
| 02/01/2006 | CN1729185A Nobel compounds having selective inhibiting effect at GSK3 |
| 02/01/2006 | CN1729183A Novel lapachone compounds and methods of use thereof |
| 02/01/2006 | CN1729181A Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 02/01/2006 | CN1729180A Piperazinyl and diazapanyl benzamides and benzthioamides |
| 02/01/2006 | CN1729178A N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines |
| 02/01/2006 | CN1729176A Tetrahydroquinoline derivatives and their use as FSH receptor modulators |
| 02/01/2006 | CN1729175A Tetrahydroquinoline derivatives |
| 02/01/2006 | CN1729173A N-(indolethyl-) cacloamine compounds |
| 02/01/2006 | CN1729172A Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity |
| 02/01/2006 | CN1729171A Modulation of anxiety through blockade of anandamide hydrolysis |
| 02/01/2006 | CN1729160A Drugs for chronic pain |
| 02/01/2006 | CN1729158A Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 02/01/2006 | CN1729157A Substituted amino phenylacetic acids, derivatives thereof, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
| 02/01/2006 | CN1729019A Wild-type RAD as a cancer therapeutic agent |
| 02/01/2006 | CN1729017A A preparation and method for weight reduction |
| 02/01/2006 | CN1729012A Method and composition for preventing and treating solid tumors |
| 02/01/2006 | CN1729007A Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection |
| 02/01/2006 | CN1729006A Treatment for reactive arthritis or bursitis |
| 02/01/2006 | CN1729005A Pharmaceutical dosage forms of biguanide-sulfonylurea combinations |
| 02/01/2006 | CN1729004A Ester combination local anesthetic |
| 02/01/2006 | CN1729003A Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate |
| 02/01/2006 | CN1729002A Exemestane as chemopreventing agent |
| 02/01/2006 | CN1729001A 4-anilino quinazoline derivatives for the treatment of abnormal cell growth |
| 02/01/2006 | CN1729000A Substituted alkyl-pyridazinones for the treatment of memory and learning malfunctions |
| 02/01/2006 | CN1728999A Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists |
| 02/01/2006 | CN1728998A Use of heterocyclic amine-type compounds as neuroprotective agents |
| 02/01/2006 | CN1728997A Amorphous form of esomeprazole salts |
| 02/01/2006 | CN1728996A Pharmaceutical compositions containing abiguanide-glitazone combination |
| 02/01/2006 | CN1728995A Dosage forms comprising a cetp inhibitor and an HMG-CoA reductase inhibitor |
| 02/01/2006 | CN1728994A Method for inhibiting cancer development by fatty acid synthase inhibitors |
| 02/01/2006 | CN1728993A Pharmaceutical composition comprising lumiracoxib |
| 02/01/2006 | CN1728992A Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity |
| 02/01/2006 | CN1728991A Combination therapy for the treatment of cancer |
| 02/01/2006 | CN1728990A Uses of adenosine A2A receptor antagonists |
| 02/01/2006 | CN1728989A Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta. |
| 02/01/2006 | CN1728988A Powdered medicaments containing a tiotropium salt and salmeterol xinafoate |
| 02/01/2006 | CN1728985A Bupropion hydrochloride solid dosage forms |
| 02/01/2006 | CN1728984A Dosing aerosols containing lecithin as a surface-active substance |
| 02/01/2006 | CN1728983A Process for the chemical stabilization of a solubilized retinoid in a solvent using a base |
| 02/01/2006 | CN1728982A Pharmaceutical formulation providing an increased biovailability of hydrophobic drugs |
| 02/01/2006 | CN1727489A Bacterial plasmids |
| 02/01/2006 | CN1727359A Compound from catarrh mollase bacterial |
| 02/01/2006 | CN1727358A Steroid saponin of alpha, beta double bond structure outside furan nucleus, preparation method and application |
| 02/01/2006 | CN1727354A Compound in category of trioside methyl salicylate, oside ester saccharide |
| 02/01/2006 | CN1727351A Method for preparing compound of vegetative phosphatidylinositol in high purity |
| 02/01/2006 | CN1727348A Derivant of cephalosporin alkene, and preparation method |
| 02/01/2006 | CN1727347A Methylene containing aminobeterocycle substitutional cephalosporin of amidinothioacetamide, preparation method and application |
| 02/01/2006 | CN1727346A Derivant of gamma carbon alkenyl cephalosporin, preparing method and application |
| 02/01/2006 | CN1727345A Derivant of Deacetoxy cephalosporanicacid, preparation and application |